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vestment, recognising the NHS budget (providing free universal healthcare) was
not unlimited. Local organisation of disinvestment policy was preferred, though
some national co-ordination was felt necessary to retain equity across geographi-
cal jurisdictions. Technologies of unproven or negligible clinical benefit, or obsolete
technologies were cited as disinvestment priorities. Respondents preferred disin-
vestment decisions be clinician-led. Other decision-making groups (e.g. patients)
were expected to be biased or not sufficiently knowledgeable about the relevant
issues. When existing technologies conferred clinical benefits to (even small num-
bers of) patients, responses suggested loss aversion, even under circumstances of
increased risks alongside these benefits. Biases are uncontrolled when using a
qualitative methodology to explore these issues. CONCLUSIONS: To maximise ac-
ceptability to taxpayers, disinvestment policy-making in Scotland should prioritise
technologies of comparatively low or unproven benefit. Decisions should be local-
ly-based and clinician-led. Future research on disinvestment should utilise quan-
titative, preference-elicitation methods to minimise potential biases.
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OBJECTIVES: With the increasing demands for health care from aging society and
rapid technological advancement, the National Health Security Office (NHSO) of
Thailand demands for the development of systematic, transparent, and participa-
tory processes for selection of new health interventions to be included into the
benefit package of universal health coverage (UC) scheme. This study reviews and
describes experiences in the development of guidelines for economic evaluation
and participatory process of key stakeholders in submission and topic selection of
new health interventions into the UC benefit package. Lessons learnt from this
initiative are drawn in order to share experiences of Thailand to other developing
countries. METHODS: Research methods comprise comprehensive literature re-
views, focus group discussion, and brainstorming meeting among key stakehold-
ers, working groups, and subcommittee members. RESULTS: Research findings
indicate that the draft guideline produced by several rounds of stakeholder con-
sultations has been gradually accepted and adjusted by policy makers and key
stakeholders. Key features of the guideline comprise a) transparency in topic se-
lection for economic appraisal with full engagement of key stakeholders; b) eco-
nomic evaluation on selected interventions using incremental cost-effectiveness
ratio (ICER); c) budget impact analysis. The ICER threshold of 1 GDP per capita for
QALY gained has been applied by the Benefit Package Subcommittee of NHSO. The
six criteria for prioritization of topics were adopted in consensus by stakeholder
consultations. In Fiscal year 2010 and 2011, this guideline was successfully applied
twice a year for topic selection, economic appraisal, and recommendations to the
sub-committee and transmitted to NHSO Board for its final decision.
CONCLUSIONS: This initiative not only produced and applied evidence informed
decisions in a transparent manner; it also strengthened and sustained institutional
capacities in generating evidence on ICER, budget impact assessment and other
ethical social considerations. The NHSO subcommittee is the platform for inter-
change between evidence and policies.
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OBJECTIVES:Healthc are reforms are inherent in any health care system across the
globe in order to take into account changes and developments worldwide on new
ways to evaluate innovative medicines. This has impacted drugs being launched in
the rare disease space. The research is aimed to understand the dynamics in pric-
ing and reimbursement environment of drugs launched in rare diseases in key
European markets. METHODS: The research involved desk research as well as
interviews with selected stakeholders in EU5, The Netherlands, Sweden, Finland
and Romania. RESULTS: In the past it was orphan drugs were able to achieve a high
price or favourable reimbursement status, largely due to International and Na-
tional OD legislation. The results inferred that factors such as the level of unmet
needs, severity of diseases, prevalence, innovation, clinical effectiveness influence
the achievable price and reimbursement. To keep up to speed to the challenges of
dynamic healthcare funding environments pharmaceutical companies have to en-
sure that the value of the product is well demonstrated with a clear value propo-
sition. When products are launched in specific markets, the HTA bodies look for
specific criteria to be fulfilled (e.g. the SMC in the UK or HAS in France).
CONCLUSIONS: Orphan drugs are facing significant challenges in the future. How-
ever, opportunities still exist for novel compounds to reach the market place and
have an impact on how rare diseases are treated. Low patient numbers, high levels
of both disease severity and unmet need and public perception can help boost the
economic argument for Orphan Drug Approval and enable strong market access.
Health Care Use & Policy Studies – Patient-Registries & Post-Marketing Studies
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OBJECTIVES: Outpatient services in Germany are less controlled by external qual-
ity assurance programs. Comprehensive outcome data for benchmarking or
health-care decision-making are missing e.g. for day case surgery. A quality-of-life
instrument specific to hernia repair with mesh has been recently proposed (Caro-
linas Comfort Scale, CCS). This study evaluates the integration of CCS as part of a
multicentre quality assurance scheme for outpatient surgery. METHODS: Sixteen
ambulant centres developed a web-based quality assurance scheme for hernia day
surgery in Germany. In an evaluation phase, all patients which were intended to
treat with 3-dimensional meshes, were registered with consensus into a database
through a web-based portal. CCS questionnaires were mailed to patients 4 and 12
weeks after surgery. Patients were requested to send pseudonymized responses to
an independent party for inputting answers into the database. Clinical examina-
tions were made 4 and 12 weeks postoperatively. Additional follow-up is planned
52 weeks after surgery. CSS consists of 23 questions in 7 activity- categories and 3
dimensions: sensation of mesh, movement limitations, pain. RESULTS:During the
first year (Oct 2009 to Sept 2010) 1429 patients were registered (1271 male, 158
female, median age 53 years) and treated for primary (88%) or recurrent (11%)
hernia. 1300 (90%)/1246 (87%) patients were clinically reviewed 4/12 weeks after
surgery. 1072 (75%) /1002 (70%) questionnaires were retrieved 4/12 weeks after
surgery. Patient satisfaction rate was 98%. CCS scores are shown to be decreased
from 4 to 12 weeks in all dimensions (Sensation: 0.51 to 0.35, Movement: 0.40 to
0.20, pain: 0.45 to 0.26). CONCLUSIONS: CCS, a short, hernia-specific quality-of-life
questionnaire, is easy to use and well accepted by patients. It is shown to be a
feasible instrument to evaluate patient reported outcome after day-case hernia
surgery in a web-based multicentre quality assurance system.
Health Care Use & Policy Studies – Population Health
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OBJECTIVES: To determine the population risk stratification based on the cost of
care (health resource use) in patients with chronic diseases in primary health care
(PC).METHODS:Multi-center observational design. We included all patients from 6
centers of PC that demanded assistance in 2010 managed by Badalona Serveis
Assistencials SA (health organization). The risk population was defined beginning
from the complexity (co-morbid chronic [CC]) and fragility (socio-demographic and
clinical criteria). Main measures: services (medical, paediatric), chronic co-morbid-
ity (CC) and direct cost model. From a group of experts identified the different
chronic conditions and population risk levels: Level 1 (no CC), level 2 (1-2 CC), level
3 (3-4 CC) and level 4 ( 5 CC). Fixed (operation) and variable costs were considered.
Statistical analysis: linear regression model (coefficient of determination [R2], de-
pendent variable: health care costs) and principal components, p0.05. RESULTS:
We included 83,090 patients, mean age 40.9 years, women: 53%. The total cost was
56.1 million / EUR. The average / unit cost: 675.3 euros. The cost for drugs was 41%.
Stratification levels: level 1 (N  36,859, 44.4%, €283.9), level 2 (N  32,644, 39.3%,
€694.8), Level 3 (N  10019, 12.1%, €1461.6, and level 4 (N  3568, 4.3%, €2331.2).
Musculoskeletal diseases (38.1%), mental (31.6%) and cardiovascular (30.4%) were
the most frequent, p 0.001. Predictive model (R2): age  23.4%, age-sex  24.1%,
age-sex-CC  41.8% (medical: 47.9%; Paediatrics: 15.1%, p 0.001). It details the
complexity and fragility of the patients for each level of stratification and clinical
services.CONCLUSIONS:The CC is associated with increased healthcare costs. The
number of co-morbidities explains much of the costs. Knowledge of the risk /
complexity / fragility of the patients should allow preventive intervention strate-
gies.
Health Care Use & Policy Studies – Prescribing Behavior & Treatment Guidelines
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OBJECTIVES: Introduction of module in rational use of medicine (RUM) to pharma-
cology curriculum needs analysis of existing knowledge among health care work-
ers. The knowledge and attitudes of medical practitioners (MPs) and medical stu-
dents (MSs) on Standard Treatment Guidelines (STG) were assessed. METHODS:
Forty-two MPs and 120 MSs were given pretested structured questionnaire on STG
and core policies of RUM. RESULTS: Results showed that only 78 % of MPs were
confident about their knowledge in STG and 7% of them were not attentive. Knowl-
edge of MPs and MSs showed 78% and 84% on contents of STG while the knowledge
in core policies was 73% and 34% respectively. More than 99% of MSs and 71% of
MPs were attentive on the inclusion of clinical features of the illness in STG. knowl-
edge on updating and significance of STG as guidance for new prescribers of MPs
were 84% and 88% respectively while 96 % of MSs had acquainted in those two
areas. Both groups had good knowledge on STG is not an accordance with person-
nel experience (MPs-71%, MSs-74%). 80% of MSs and 75% MPs discerned that com-
mon treatment practices is not an inclusion criteria for STG. CONCLUSIONS: We
found that MSs had good knowledge about the contents of STG and skills in appli-
cation in RUM are limited. MPs were detailed on core policies & application of STG
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